Emily Heffernan of Arcadis explains how facility scale, equipment, containment, and quality testing differ across ex vivo cell therapy, viral vector, and mRNA-LNP manufacturing.
Emily Heffernan
Advertisement
Emily Heffernan, US director new process technologies at Arcadis is a process subject matter expert, specializing in biological process and facility design. With more than 20 years’ experience, her expertise spans across multiple therapeutic areas including monoclonal antibodies, vaccines, cell and gene therapies, and RNA therapeutics.
Articles by Emily Heffernan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5